Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015, we would like to inform you that the Rising Pharma Holdings, Inc. USA, a marketing and distribution partner of Bliss GVS Pharma Limited ( the Company ) has been granted final approval from the U.S. Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) for its product Mesalamine Suppositories 1000 mg . The ANDA was submitted through our partner in the USA.'.